Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.

Abstract

The results were compared with published data. We found clearly skewed distribution of tumor doses, with a majority of tumors receiving only a few mGy per MBq administered activity. In some patients, however, doses did reach 20 mGy MBq(-1).